Skip to main content
OpenTrials
Completed

NCT Number: NCT05157594

hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors

PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included. Blood samples will be taken during their therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glial Cell Tumors Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Jean PERRIN

Clermont-Ferrand, 63011, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female or male 18 years of age or older.
  • Patients with a high grade primary glial tumor (Astrocytoma grade 3; Glioblastoma; Anaplastic Oligodendroglioma)
  • Patients scheduled to begin radiation and/or chemotherapy.
  • Able to give informed consent to participate in the research.
  • Enrolled in a social security plan or beneficiary of such a plan.

Exclusion criteria

  • Patient under guardianship or curatorship
  • Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social reasons (deprivation of liberty by judicial or administrative decision) or geographical reasons that could compromise the medical follow-up of the trial.
  • Refusal to participate.
  • Pregnant or breastfeeding woman.

Treatment and study plan

Blood sample

Biological

Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.

Primary outcomes

  1. Plasma concentrations of hPG80

    Time frame: From Radiotherapy 1st session to 9 month follow-up

    To evaluate plasma concentrations of hPG80 (circulating progastrin) during therapeutic and recurrence follow-up in patients with high-grade brain tumors.

Secondary outcomes

  1. hPG80 concentration according to tumor progression

    Time frame: Through study completion, an average of 1 year and 6 months

    To study hPG80 concentration according to tumor progression in patients with high-grade brain tumor

  2. Sensitivity of hPG80 concentration changes to irradiation

    Time frame: Through study completion, an average of 1 year and 6 months

    To evaluate the sensitivity of hPG80 concentration changes to irradiation in patients with high-grade brain tumor.

  3. Interindividual variations of hPG80 concentration

    Time frame: Through study completion, an average of 1 year and 6 months

    To compare the plasma expression level of hPG80 in patients with high-grade brain tumor to study interindividual variations around and during disease management.

Sponsors and collaborators

Lead sponsor

Centre Jean Perrin

Other

Collaborators

  • ECS Progastrin

Registry information

Official study title

Pilot Study of hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors

Acronym: PROGLIO

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Dec 15, 2021
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.